Biotech Values

[DewDiligence]

>> IL-9 is in MEDI's hands. If they drop it, it becomes more important, not less, to have a pulmonary specialist to find a new partner or continue the development internally. <<

My hypothesis is that Holroyd quit on his own volition. The suddenness of the action (evidenced, as you noted, by the need for an “acting” CMO) also points in that direction.